Introduction
Lin28 is an evolutionarily conserved RNA-binding protein that has a critical role in developmental timing in Caenorhabditis elegans (Moss et al., 1997) . In the mouse, Lin28 is widely expressed in early stage embryos, with expression declining and becoming restricted to a limited number of tissues as embryonic development proceeds (Yang and Moss, 2003) . In human tissues, Lin28 expression has been detected in normal ovarian surface epithelium (Viswanathan et al., 2009) as well as in mature oocytes (Assou et al., 2009 ). Lin28 expression is high in human and mouse embryonic stem (ES) cells, and decreases dramatically during ES cell differentiation (Richard et al., 2004; Darr and Benvenisty, 2008) . The biological importance of Lin28 is further underscored by its ability to facilitate the reprograming of human somatic cells to induced pluripotent stem cells (Yu et al., 2007) .
Lin28 has pleiotropic roles in the regulation of gene expression. It has been shown to block the processing of let-7 microRNAs (Heo et al., 2008; Newman et al., 2008; Rybak et al., 2008; Viswanathan et al., 2008) as well as a handful of other microRNAs (Heo et al., 2009; Trabucchi et al., 2009 ). In addition, Lin28 has been reported by us and others to bind to a specific subset of mRNAs, including those for IGF-2, Oct4, and several cell cycle-related factors, thereby modulating their translation (Polesskaya et al., 2007; Qiu et al., 2009; .
The ability of Lin28 to regulate the expression of a subset of cell cycle-related genes and microRNAs suggests a link between Lin28 and cancer cell growth control. Indeed, one recent report suggests that such a link exists, and specifically connects Lin28 expression with a signal-transduction cascade that may contribute to breast cancer metastasis in a mouse model (DangiGarimella et al., 2009 ). In the case of epithelial ovarian cancer (EOC), however, contradictory findings have emerged. On the basis of the publicly accessible microarray data obtained by analysis of EOC tumors, Viswanathan et al. (2009) have reported that Lin28 is predominantly expressed in tumors of advanced histological grade. The authors also detected Lin28 expression in normal ovarian surface epithelium; this cell type is thought to contribute, at least in part, to the origin of EOC. In contrast, Lu et al. (2009) have found no significant correlation between Lin28 expression levels and tumor grade, disease stage or overall survival. The possibility exists that these discrepancies result from RNA-based analyses that do not faithfully reflect expression at the protein level. Thus, the contribution of Lin28 to the etiology and progression of EOC remains to be clarified.
The transcription factor Oct4 also has a pivotal role in the maintenance of pluripotency in ES cells (Pei, 2009) . In one breast cancer cell line, Oct4 expression was detected and suggested to have a role in the survival of these cells (Hu et al., 2008) . Oct4 expression is also detectable in embryonic carcinoma and germ cell tumors, which exhibit properties of pluripotentiality (Cheng et al., 2007) . Although Oct4 expression has been proposed as a diagnostic tool for the evaluation of germ cell tumors (Cheng et al., 2007) , its expression and role in EOC have not yet been documented.
In this study, we show that a sub-population of human EOC cells express both Lin28 and Oct4, and that this co-expression pattern is significantly associated with increased tumor grade. Importantly, we show that inhibition of either Lin28 or Oct4 expression leads to decreased cell viability, and that their combined repression results in synergistic inhibition of cancer cell growth and survival. Together, these results suggest that the expression of Lin28 and Oct4 may be deregulated in certain adult solid tumors, where these proteins may have important roles in the etiology and progression of cancer, including the development of tumor heterogeneity, which may contribute to the selection of the drugresistant phenotype in certain tumor cell populations.
Results

Lin28 and Oct4 expression in human cancer cell lines
We have found that a subset of human ovarian cancer and embryonic carcinoma cell lines express both Lin28 and Oct4. As shown in Figure 1a , at the mRNA level, Lin28 expression is highest in the embryonic carcinoma PA-1 cell line, followed by the ovarian cancer cell line, IGROV1. IGROV1 was originally derived from a stage III ovarian cancer patient with a tumor of endometroid, serous clear and undifferentiated cells. The IGROV1 cell line was found to be fast growing and highly tumorigenic in nude mice (Benard et al., 1985) . Lin28 mRNA was barely detectable in the ovarian cancer-derived cell line, A2780, and was not detectable in the CaOV3, SKOV3 or OVCA432 cell lines. In this regard, the expression pattern of Oct4 mRNA is positively correlated with the pattern of Lin28 mRNA (Figure 1a) .
At the protein level, the expression patterns of both Lin28 and Oct4 parallel those of their respective mRNAs (Figure 1b , and data not shown). Although Lin28 expression in the PA-1 and A2780 cell lines has been reported previously (Moss and Tang, 2003; Viswanathan et al., 2009) , the co-expression of proteins Lin28 with Oct4 in these cells has not been reported previously.
As one approach to better understanding the functional significance of these proteins in cancer cells, we examined Lin28 and Oct4 expression in both the PA-1 and IGROV1 lines by immunofluorescence. In both lines Oct4 localizes to the cell nucleus (Figure 2A , panels b and f), whereas Lin28 is detectable in both the nucleus and in the cytoplasm (Figure 2A , panels c and g). This is consistent with our nucleocytoplasmic fractionation results showing that Lin28 is present in both of these compartments, whereas Gapdh and Oct4 are present only in the cytoplasm or in the nucleus, respectively ( Figure 2B ). The appearance of nearly equal partitioning of Lin28 between the cytoplasm and the nucleus as illustrated in Figure 2B is deceptive, however, because twofold more material from the nuclear fraction than the cytoplasmic fraction was loaded on this particular gel, so that the Oct4 signal ( Figure 2B , bottom panels) would be visible for presentation in this report.
Differences in the pattern of expression of these two proteins are also apparent at the cell population level. Notably, Lin28 and Oct4 are both uniformly expressed throughout the population of PA-1 cells ( Figure 2A , panel d). In contrast, not all IGROV1 cells express these two factors ( Figure 2A , panel h). In this cell line, the majority of cells express both Lin28 and Oct4 ( Figure 2A ; red arrow), whereas some cells express only one of these two markers (Figure 2A ; green arrow or red arrowhead). Yet a third population of IGROV1 cells expresses neither of these proteins (Figure 2A ; white 
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S Peng et al 2154 arrowhead). Although the heterogeneity observed here may be the result of selection in cell culture (that is, it is well known that stem cells lose their pluripotency under culture conditions that do not support undifferentiated growth), it nonetheless raises the intriguing possibility that those cells that express both Lin28 and Oct4 represent a sub-population of cells that have retained certain 'cancer stem cell' (CSC) properties, whereas those cells expressing only Lin28 or Oct4 (or neither) may represent cells that lie further down the differentiation pathway. Support for this concept in EOC is presented by our in vivo analyses of EOC tumor samples, as described below. In this regard, tumor growth potential may depend on the presence of CSCs that have the ability to self-renew, and thereby repopulate the tumor mass (Fodde, 2009; Jinawath et al., 2009; Jordan, 2009; Marotta and Polyak, 2009) . In this context, tumor cells positive for both of these two stem cell markers (that is, the majority of cells in both the PA-1 and IGROV1 cell lines) would represent CSC candidates. The diversity of stem cell marker staining observed in the IGROV1 cell line studied here supports the emerging concept that CSC-like properties may contribute to the phenotypic heterogeneity observed in EOC. The high frequency of the development of drug resistance and concomitant disease recurrence in EOC patients (Vasey, 2008; Alvero et al., 2009) further suggests the possible presence of such CSCs in these tumors.
Lin28 and Oct4 expression in human ovarian tumor samples Although these cell line data are informative, only a limited number of cell lines were studied, and cell lines do not always accurately represent the phenotype of the tumors from which they were derived. We, therefore, analyzed a series of tumor samples obtained from patients with a confirmed diagnosis of ovarian cancer. The pattern of expression of both Lin28 and Oct4 in EOC tumors recapitulates what we observed in the ovarian cancer-derived cell lines; the majority of these EOC tumor samples exhibit heterogeneous patterns of both Lin28 and Oct4 expression. We analyzed a total of 14 human ovarian tumor samples of various histological subtypes by immunohistochemistry. As shown in Table 1 , six of the seven (85.7%) poorly differentiated tumors stained positively for both Lin28 and Oct4, whereas four of the five (80%) moderately or welldifferentiated tumors, and two of the two benign tumors (100%) were negative for both markers. The expression Western blot analyses of proteins extracted from PA-1 (upper panels) and IGROV1 (bottom panels) cells. Aliquots of cytoplasmic (lanes 1) and nuclear (lanes 2) proteins were resolved by SDS-polyacrylamide gel electrophoresis, followed by western blot analyses using the antibodies indicated on the right. Twofold more materials from the nuclear than from the cytoplasmic fractions were loaded. Sub-population of EOC cells co-expresses Lin28 and Oct4 S Peng et al of neither marker was correlated with histological subtype. Statistical analysis using Spearman's rank correlation coefficient was used to assess the relationship between the co-expression of Lin28 and Oct4 and tumor grade. We found that there is a significantly positive correlation between co-expression of Lin28 and Oct4 and poorly differentiated tumors (Po0.01). Although this analysis was performed on a small sample population, these results nonetheless suggest the intriguing possibility that expression of both Lin28 and Oct4 in ovarian cancer tissues may be an indication of poor differentiation, and therefore may predict a less favorable outcome.
In Figure 3 , we show representative images from these immunohistochemical analyses. In one specimen from a patient with a poorly differentiated endometroid ovarian adenocarcinoma, the majority of cells stain positively with the epithelial marker protein cytokeratin (panel c), and are also positive for expression of Lin28 (panel a) and Oct4 (panel b). No staining was observed when normal rabbit serum or mouse preimmune immunoglobulin G was used as negative controls (panel d, and data not shown). These results confirm the expression of Lin28 and Oct4 in EOC tumor cells and further show that in this particular tumor the majority of cancer cells express both Lin28 and Oct4. Although properties of the primary antisera used in this study precluded colabeling with both Lin28 and Oct4 using the same tissue sections, we were able to estimate the percentage of cancer cells that stain positively for either marker using morphometric methods. On the basis of this analysis, we estimate that in this EOC sample, B60% of tumor cells are positive for Lin28, and B75% of cells are positive for Oct4. This distribution pattern suggests that 45% of cancer cells in this sample express both Lin28 and Oct4, another B45% express only one of these two proteins and B10% express neither protein. As further study will be required to confirm this interpretation, these observations are consistent with our in vitro IGROV1 study (see Figure 2) . Similarly, in vivo expression of both Lin28 and Oct4 in these tumor samples appears to be both cytoplasmic and nuclear (inserts in panels a and b), in contrast to the cytokeratin-staining pattern, which is predominantly cytoplasmic (Figure 3c insert) . These results are consistent with recent reports on Oct 4 expression in other tumors, in which it has been found to be localized in both the nuclear and cytoplasmic compartments (Cheng et al., 2007; Chen et al., 2009 ), although they are in contrast to our observations in at least certain tumorderived cell lines, in which Oct4 appears to be localized exclusively in the nucleus of cancer-derived cell lines (see Figure 2 ). The significance of this discrepancy in localization patterns, if any, and the possible functional consequence will require further study.
Downregulation of the expression of Lin28 and Oct4 reduces cell viability
To address whether Lin28 has a role in cancer cell growth as it does in mouse ES cells , we reduced Lin28 expression using two different sets of small interfering RNAs (siRNA) specific for Lin28. siLin28 reduced Lin28 mRNA expression levels by B90 and 80% (compared with control siRNA) in both the PA-1 and IGROV1 cell lines, respectively, and siLin28-2 reduced Lin28 mRNA expression levels by B82 and 65%, respectively (Figure 4a) . Importantly, the untargeted Oct4 and b-tubulin mRNAs were not significantly affected by these treatments, confirming the specificity of these siRNAs. At the Lin28 protein level, we observed B80 and 70% decreases using siLin28 and siLin28-2, respectively, in PA-1 cells (Figure 4b , compare lanes 3 and 2 with lane 1), and B40 and 20% decreases in IGROV1 cells (compare lanes 6 and 5 with lane 4), after normalization against the b-actin loading control.
When Lin28 expression was downregulated using siLin28, we observed B65 and 50% decrease in cell viability in PA-1 and IGROV1, respectively, whereas using siLin28-2, we observed B40% decrease in cell viability in both PA-1 and IGROV1 cells (Figure 4c ). The reduced cell viability observed when Lin28 expression was inhibited was unlikely the result of changes in cell death rates, as caspase activity assays (a measurement of apoptosis) showed no significant differences between the Lin28 siRNA and control siRNA-treated cells (Figure 4d ). These results are consistent with the hypothesis that Lin28 is involved in regulating cancer cell growth, similar to its functional role in regulating 
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S Peng et al mouse ES cell growth ). However, the possibility exists that Lin28 may also have a role in apoptosis, which has not yet been uncovered due to the incomplete Lin28 knockdown in the cells (there was still 20-60% of Lin28 protein present in the siLin28-treated group, Figure 4b) .
In analogous experiments, we also tested the functional role of Oct4 in these same cancer-derived cell lines using siRNA methods. Oct4 previously has been reported to have a role in the survival of breast cancer cells by suppression of apoptosis (Hu et al., 2008) . Thus, we reduced Oct4 expression using siRNAs specific for Oct4 (siOct4), followed by cell viability analysis. We observed a B60% viability reduction in PA-1 cells transfected with siOct4 compared with control siRNA (Figure 4e , upper panel, compare yellow bar with blue bar). Caspase activity assays indicated that the reduced cell viability observed was in part the result of increased apoptosis (Figure 4e , bottom panel, compare yellow bar with blue bar). Strikingly, when cells were simultaneously treated with siLin28 and siOct4 (using the same total amount of siRNA, that is, the amounts of siLin28 and siOct4 were each reduced by half), we observed a dramatic decrease in cell viability (Figure 4e , up panel, green bar) as well as a corresponding increase in caspase activity (Figure 4e , bottom panel, green bar). This double-knockdown effect appears to be synergistic, as the additive effects derived from individual treatments with either siLin28 alone (Figure 4e , red bars) or siOct4 alone (yellow bars) were significantly less than those observed in the double-knockdown-treated cells (Figure 4e, green bars) . In support of this finding, similar results were also obtained using the EOC-derived IGROV1 cell line (data not shown).
Discussion
We have shown here that the expression pattern of the two ES cell markers Lin28 and Oct4 is more extensive, and also more complex, than has been reported previously, and includes co-expression in ovarian cancer cells. In fact, there is a significant correlation between the co-expression of these markers and advanced tumor grade in malignant ovarian tumors. This observation is consistent with a proposed functional role for these two proteins in the regulation of ovarian cancer cell growth and survival. Inhibition of Lin28 and Oct4 expression, singly, and in combination, leads to a significant decrease in cancer cell growth and survival, and the 
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Lin28 is known to block the production of a group of microRNAs, including let-7 microRNAs, which have been implicated previously in the regulation of cell proliferation and differentiation (Bussing et al., 2008; Heo et al., 2009; Trabucchi et al., 2009) . The observed growth inhibition following Lin28 repression is likely the result, at least in part, of a restoration in let-7 microRNA expression, which has been linked to a translational blockade of target mRNAs involved in promoting cell cycle progression (Bussing et al., 2008) . These results are also consistent with our previous observations, demonstrating that Lin28 has a direct role in modulating the expression of certain cell cycle-related genes, including cyclin A, cyclin B, cdk4 and histone H2a in mouse ES cells . In this study, we speculate that decreased expression of some of these cell cycle regulatory genes in cancer cells may also contribute to the growth inhibition observed.
Recent studies further suggest that Oct4 also has a role in regulating cell proliferation and survival partly by inhibition of apoptosis through an Oct4/Tcl1/Akt1 signaling pathway (Hu et al., 2008) . The co-expression of Lin28 and Oct4 in a sub-population of high-grade ovarian cancer cells is particularly intriguing, given that both genes have critical roles in the maintenance of pluripotency, and hence the production of induced pluripotent stem cells (Yu, et al., 2007; Heo et al., 2009; Pei, 2009 ). Importantly, we have found that Lin28 specifically binds to Oct4 mRNA and stimulates its translation in both human ES cells and embryonic carcinoma PA-1 cells (Qiu et al., 2009 ). This may explain, at least in part, the observed synergistic effects of the Lin28/Oct4 double-knockdown in the tumor cells (Figure 4e ). Together, these observations have important implications for the existence of CSCs in adult solid tumors, and the diagnostic methods that may be useful for the identification of this important tumor cell subpopulation. On the basis of the significant synergistic effects of Lin28 and Oct4 double-knockdown on cancer cell growth and survival in vitro, here we propose that Lin28 and Oct4 may also serve as potential therapeutic targets for the development of novel strategies for the treatment of ovarian cancer.
Materials and methods
Antibodies and siRNAs
The polyclonal anti-Lin28 (Abcam, Cambridge, MA, USA, ab46020), normal rabbit serum (SouthernBiotech, Birmingham, AL, USA, 0040-01), mouse preimmune immunoglobulin G (Chemicon PP54, Temecula, CA, USA), monoclonal anti-Oct4 (Santa Cruz, Santa Cruz, CA, USA, sc-5279), anti-b-actin (Sigma, Saint Louis, MO, USA, A2228), and anti-cytokeratin (DAKO, Glostrup, Denmark, M351501-2) antibodies were purchased. siLin28 (ON-TARGETplus SMARTpool, L-018411-01), siLin28-2 (an equal molar mixture of two siRNAs J-018411-09 and J-018411-11), ConsiRNA (D-001810-10-05), and siOct4 (L-019591-00) were purchased from Dharmacon (Lafayette, CO, USA).
Tissue microarray analyses
Formalin-fixed and paraffin-embedded human ovarian cancer tissue microarray slides (YTMA # 172) were purchased from Yale Pathology Tissue Services (New Haven, CT, USA).
Cell culture, cell extracts and siRNA transfection The cell lines IGROV1 and A2780 were gifts from Drs Philip Low and Gil Mor, respectively. The PA-1 cell line was obtained from American Type Culture Collection. Cell extracts from CaOV3, SKOV3 and OVA432 were gifs from Dr Jill Reiter. IGROV1, PA-1 and A2780 cells were maintained in folate-free RPMI medium 1640 (Gibco, Grand Island, NY, USA, 27016) supplemented with 10% fetal bovine serum, 1 mM l-glutamine, and 1% penicillin-streptomycin. siRNA transfections were carried out as previously described (Zhang et al., 2007) .
Nuclear and cytoplasmic protein fractionation These were performed using the Subcellular Protein Fractionation Kit (Thermo Scientific, Cincinnati, OH, USA, 78840) according to the manufacturer's instructions.
Cell viability and caspase-3/7 assays Viability assays were performed using the CellTiterBlue Cell Viability kit (Promega, Madison, WI, USA), and caspase activities measured using the Apo-ONE Homogeneous Caspase-3/7 Assay kit (Promega), according to the manufacturer's protocols.
Immunofluorescence
These were carried out as described previously (Zhang et al., 2008) . The polyclonal anti-Lin28 and the monoclonal antiOct4 were used at 1:2000 and 1:500 dilutions, respectively.
Immunohistochemistry
These were performed using the EnVision G/2 Doublestain Kit (catalog number K5361, DAKO), according to the manufacturer's protocol. The anti-Lin28, anti-Oct4, and anti-cytokeratin antibodies were used at 1:7000, 1:200 and 1:500 dilutions, respectively. Normal rabbit serum and mouse preimmune immunoglobulin G at the same immunoglobulin G concentrations were used as negative controls for the antibodies.
RNA extraction and reverse transcription and quantitative realtime PCR These were carried out on the basis of the protocols described previously 
Morphometric analysis
Lin28 or Oct4-positive cells on tissue microarray slides were counted under a light microscope. Three fields were randomly chosen for Lin28 or Oct4-positive cell counting, with each field containing at least 100 cells. The total numbers of Lin28 or Oct4-positive cells from three fields were divided by the combined total cell numbers to generate the percentage of Lin28 or Oct4-positive cells in each tumor sample.
